These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32547195)

  • 1. Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway.
    Hu H; Liu Y; Tan S; Xie XX; He J; Luo F; Wang L
    Cancer Manag Res; 2020; 12():3579-3587. PubMed ID: 32547195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
    Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade.
    Yang Q; Ni L; Imani S; Xiang Z; Hai R; Ding R; Fu S; Wu JB; Wen Q
    Cancer Manag Res; 2020; 12():4937-4948. PubMed ID: 32606981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.
    Ji Y; Li X; Qi Y; Zhao J; Zhang W; Qu P
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36558006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
    Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
    Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anlotinib suppressed tumor cell proliferation and migration in hypopharyngeal carcinoma.
    Song H; Song Q; Zhao X; Yang Y; Mou Y; Li Y; Song X
    Braz J Otorhinolaryngol; 2024; 90(2):101397. PubMed ID: 38330738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
    Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
    Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity.
    Li Z; Tian J; Du L; Gao Y; Wang Y; You F; Wang L
    J Cell Mol Med; 2021 Jun; 25(12):5547-5559. PubMed ID: 33955683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.
    Luo Q; Zhang S; Zhang D; Feng R; Li N; Chen W; Chen X; Yang S
    Curr Pharm Biotechnol; 2021; 22(4):523-533. PubMed ID: 32576126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity
    Xu X; Wang Q; Shen L; Shen Y; Liu H; Liu Y; Yang Z; Hoffman RM; Feng W
    Anticancer Res; 2024 Apr; 44(4):1399-1407. PubMed ID: 38538004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis.
    Zhu Y; Wang X; Chen Z; Zhou L; Di X; Fan P; He Z
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.
    Song P; Song B; Liu J; Wang X; Nan X; Wang J
    Clin Transl Oncol; 2021 Apr; 23(4):892-901. PubMed ID: 32974862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C.
    Fang F; Yuan Q
    Oncol Lett; 2022 Feb; 23(2):46. PubMed ID: 34976158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 16. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib suppresses proliferation, migration, and immune escape of gastric cancer cells by activating the cGAS-STING/IFN-β pathway.
    Yuan M; Guo XL; Chen JH; He Y; Liu ZQ; Zhang HP; Ren J; Xu Q
    Neoplasma; 2022 Jul; 69(4):807-819. PubMed ID: 35471977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.
    Liu X; Sun L; Zhang S; Zhang S; Li W
    J Cell Physiol; 2020 Nov; 235(11):7747-7756. PubMed ID: 31681988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
    Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
    Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer.
    Zheng W; Sun G; Li Z; Wu F; Sun G; Cao H; Zhou J; Ma Y
    Front Surg; 2022; 9():895982. PubMed ID: 35495754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.